PROPRANOLOL PLUS LIGATION REDUCES RECURRENCE OF ESOPHAGEAL VARICES?
Launched by FEDERAL UNIVERSITY OF SÃO PAULO · Jul 8, 2013
Trial Information
Current as of April 27, 2025
Completed
Keywords
ClinConnect Summary
BACKGROUND AND AIMS
Bleeding from esophagogastric varices (EV) is a major complication of portal hypertension. Beta-blockers are a well-established cornerstone of portal hypertension treatment. Band ligation is the best endoscopic treatment to prevent EV bleeding. The exact benefit of beta-blocker association to band ligation remains to be defined, especially for primary prophylaxis. This prospective randomized controlled trial will compare EBL with propranolol and EBL alone in primary prophylaxis of variceal bleeding among cirrhotic patients with high-risk varices. PATIENTS AND METHODS: T...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Liver cirrhosis with esophageal varices
- • Age between 18 and 78 years
- • Accept to participate
- Exclusion Criteria:
- • Portal hypertension by schistosomiasis
- • Contraindications for propranolol use
- • Do not accept to participate
About Federal University Of São Paulo
The Federal University of São Paulo (Universidade Federal de São Paulo - UNIFESP) is a prestigious institution dedicated to advancing education, research, and healthcare in Brazil. Renowned for its commitment to innovation and excellence, UNIFESP plays a pivotal role in clinical research, focusing on a multidisciplinary approach to improve health outcomes. The university fosters collaboration among researchers, healthcare professionals, and community stakeholders, ensuring that clinical trials conducted under its auspices adhere to rigorous ethical standards and contribute valuable insights to the medical field. With a rich history of academic achievement and a strong emphasis on translational research, UNIFESP is a key player in the development of new therapies and medical interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
São Paulo, , Brazil
Patients applied
Trial Officials
Danielle Q Bonilha, MD
Principal Investigator
Federal University of São Paulo
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials